HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jhanwar, Y. S. Articles by Divgi, C. Search for Related Content PubMed PubMed Citation Articles by Jhanwar, Y. S. Articles by Divgi, C.

Current Status of Therapy of Solid Tumors

Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York

View larger version (25K): [in a new window]   FIGURE 1. Anterior (left) and posterior (right) images at various times after intraperitoneal administration of 111In-labeled humanized anti-Ley antibody hu3S193.

View larger version (29K): [in a new window]   FIGURE 2. (A) Anterior (left) and posterior (right) whole-body images obtained 3 d after administration of 131I-chimeric G250. Targeting to known lesions in scalp, hilum, and lung is excellent. (B) CT (top row) and SPECT (bottom row) coregistered images demonstrate uniform distribution throughout left hilar mass in same patient.

View larger version (10K): [in a new window]   FIGURE 3. Tumor pretargeting with bispecific construct. Bispecific agent (e.g., bispecific antibody or antibody/streptavidin fusion) is administered and saturates antigenic sites on tumor. Subsequently, a small radionuclide carrier is administered and binds to the tumor-localizing bispecific agent.